(BTMD) biote - Ratings and Ratios
Hormone Replacement Therapy, Dietary Supplements, Pellet Insertion Kits
BTMD EPS (Earnings per Share)
BTMD Revenue
Description: BTMD biote
Biote Corp is a practice-building company in the hormone optimization space, providing training and certification to physicians and nurse practitioners in bioidentical hormone replacement pellet therapy. The companys comprehensive platform, Biote Method, offers education, training, and practice management software to certified practitioners, enabling them to manage inventory, track orders, and access marketing support.
To assess Biote Corps performance, we can examine key performance indicators (KPIs) such as revenue growth, customer acquisition costs, and customer retention rates. Given the companys business model, its likely that the number of certified practitioners and the average revenue per user (ARPU) are crucial metrics. As a trading analyst, Id like to see data on the companys sales channels, customer demographics, and market penetration to better understand its competitive position.
From a financial perspective, Biote Corps market capitalization is approximately $206.89 million, with a relatively low P/E ratio of 7.28, indicating potentially undervalued shares. The negative return on equity (RoE) of -18.92% suggests that the company is currently unprofitable, which may be due to investments in growth initiatives or research and development. To gauge the companys future prospects, Id analyze its cash flow statements, operating expenses, and research and development expenditures to determine if its on track to achieve profitability.
To further evaluate Biote Corps potential, Id consider industry trends, such as the growing demand for hormone optimization therapies, and the competitive landscape, including the presence of established players and potential new entrants. By examining these factors, we can better understand Biote Corps position within the market and its potential for long-term growth.
BTMD Stock Overview
| Market Cap in USD | 164m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-04-28 |
BTMD Stock Ratings
| Growth Rating | -51.6% |
| Fundamental | 78.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -50.9% |
| Analyst Rating | 4.83 of 5 |
BTMD Dividends
Currently no dividends paidBTMD Growth Ratios
| Growth Correlation 3m | -61.6% |
| Growth Correlation 12m | -78.9% |
| Growth Correlation 5y | -54.9% |
| CAGR 5y | -4.85% |
| CAGR/Max DD 3y | -0.07 |
| CAGR/Mean DD 3y | -0.17 |
| Sharpe Ratio 12m | -1.04 |
| Alpha | -52.56 |
| Beta | 0.373 |
| Volatility | 58.45% |
| Current Volume | 129.6k |
| Average Volume 20d | 161.9k |
| Stop Loss | 3.2 (-7.2%) |
| Signal | 0.72 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (31.3m TTM) > 0 and > 6% of Revenue (6% = 11.9m TTM) |
| FCFTA 0.33 (>2.0%) and ΔFCFTA 12.88pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -0.52% (prev 8.28%; Δ -8.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.40 (>3.0%) and CFO 41.5m > Net Income 31.3m (YES >=105%, WARN >=100%) |
| Net Debt (-10.2m) to EBITDA (56.2m) ratio: -0.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (37.0m) change vs 12m ago 11.75% (target <= -2.0% for YES) |
| Gross Margin 71.89% (prev 68.44%; Δ 3.45pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 201.4% (prev 201.5%; Δ -0.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.19 (EBITDA TTM 56.2m / Interest Expense TTM 12.5m) >= 6 (WARN >= 3) |
Altman Z'' 0.58
| (A) -0.01 = (Total Current Assets 49.5m - Total Current Liabilities 50.5m) / Total Assets 104.8m |
| (B) -0.76 = Retained Earnings (Balance) -79.5m / Total Assets 104.8m |
| (C) 0.53 = EBIT TTM 52.5m / Avg Total Assets 98.8m |
| (D) -0.43 = Book Value of Equity -79.5m / Total Liabilities 183.6m |
| Total Rating: 0.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.77
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 14.00% = 5.0 |
| 3. FCF Margin 17.57% = 4.39 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 1.87 = 0.25 |
| 6. ROIC - WACC 32.43% = 12.50 |
| 7. RoE data missing |
| 8. Rev. Trend 79.76% = 3.99 |
| 9. Rev. CAGR 5.69% = 0.71 |
| 10. EPS Trend 17.27% = 0.43 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BTMD shares?
Over the past week, the price has changed by +0.00%, over one month by +18.15%, over three months by -13.32% and over the past year by -41.62%.
Is biote a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BTMD is around 2.94 USD . This means that BTMD is currently overvalued and has a potential downside of -14.78%.
Is BTMD a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BTMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.9 | 41.4% |
| Analysts Target Price | 4.9 | 41.4% |
| ValueRay Target Price | 3.2 | -8.4% |
Last update: 2025-09-04 04:33
BTMD Fundamental Data Overview
CCE Cash And Equivalents = 19.6m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 3.8977
P/E Forward = 7.7942
P/S = 0.8245
P/B = 2.9604
Beta = 1.21
Revenue TTM = 199.1m USD
EBIT TTM = 52.5m USD
EBITDA TTM = 56.2m USD
Long Term Debt = 98.5m USD (from longTermDebt, last quarter)
Short Term Debt = 6.81m USD (from shortTermDebt, last quarter)
Debt = 105.3m USD (Calculated: Short Term 6.81m + Long Term 98.5m)
Net Debt = -10.2m USD (from netDebt column, last quarter)
Enterprise Value = 249.8m USD (164.1m + Debt 105.3m - CCE 19.6m)
Interest Coverage Ratio = 4.19 (Ebit TTM 52.5m / Interest Expense TTM 12.5m)
FCF Yield = 14.00% (FCF TTM 35.0m / Enterprise Value 249.8m)
FCF Margin = 17.57% (FCF TTM 35.0m / Revenue TTM 199.1m)
Net Margin = 15.73% (Net Income TTM 31.3m / Revenue TTM 199.1m)
Gross Margin = 71.89% ((Revenue TTM 199.1m - Cost of Revenue TTM 56.0m) / Revenue TTM)
Tobins Q-Ratio = -3.14 (set to none) (Enterprise Value 249.8m / Book Value Of Equity -79.5m)
Interest Expense / Debt = 2.71% (Interest Expense 2.85m / Debt 105.3m)
Taxrate = 95.47% (970.0k / 1.02m)
NOPAT = 2.38m (EBIT 52.5m * (1 - 95.47%))
Current Ratio = 0.98 (Total Current Assets 49.5m / Total Current Liabilities 50.5m)
Debt / EBITDA = 1.87 (Net Debt -10.2m / EBITDA 56.2m)
Debt / FCF = 3.01 (Debt 105.3m / FCF TTM 35.0m)
Total Stockholder Equity = -100.4m (last 4 quarters mean)
RoA = 29.87% (Net Income 31.3m, Total Assets 104.8m )
RoE = unknown (Net Income TTM 31.3m / Total Stockholder Equity -100.4m)
RoCE = unknown (Ebit 52.5m / (Equity -100.4m + L.T.Debt 98.5m))
RoIC = 36.98% (NOPAT 2.38m / Invested Capital 6.43m)
WACC = 4.55% (E(164.1m)/V(269.4m) * Re(7.39%)) + (D(105.3m)/V(269.4m) * Rd(2.71%) * (1-Tc(0.95)))
Shares Correlation 3-Years: 81.82 | Cagr: 15.46%
Discount Rate = 7.39% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈28.6m ; Y1≈18.8m ; Y5≈8.59m
Fair Price DCF = 5.33 (DCF Value 168.8m / Shares Outstanding 31.7m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 79.76 | Revenue CAGR: 5.69%
Rev Growth-of-Growth: -1.29
EPS Correlation: 17.27 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 47.80
Additional Sources for BTMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle